BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 9420278)

  • 1. Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product.
    Underwood MR; Harvey RJ; Stanat SC; Hemphill ML; Miller T; Drach JC; Townsend LB; Biron KK
    J Virol; 1998 Jan; 72(1):717-25. PubMed ID: 9420278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56.
    Krosky PM; Underwood MR; Turk SR; Feng KW; Jain RK; Ptak RG; Westerman AC; Biron KK; Townsend LB; Drach JC
    J Virol; 1998 Jun; 72(6):4721-8. PubMed ID: 9573236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27.
    Komazin G; Ptak RG; Emmer BT; Townsend LB; Drach JC
    J Virol; 2003 Nov; 77(21):11499-506. PubMed ID: 14557635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action.
    Biron KK; Harvey RJ; Chamberlain SC; Good SS; Smith AA; Davis MG; Talarico CL; Miller WH; Ferris R; Dornsife RE; Stanat SC; Drach JC; Townsend LB; Koszalka GW
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2365-72. PubMed ID: 12121906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphorylation of beta-D-ribosylbenzimidazoles is not required for activity against human cytomegalovirus.
    Krosky PM; Borysko KZ; Nassiri MR; Devivar RV; Ptak RG; Davis MG; Biron KK; Townsend LB; Drach JC
    Antimicrob Agents Chemother; 2002 Feb; 46(2):478-86. PubMed ID: 11796361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of a mutation in human cytomegalovirus gene UL104 in resistance to benzimidazole ribonucleosides.
    Komazin G; Townsend LB; Drach JC
    J Virol; 2004 Jan; 78(2):710-5. PubMed ID: 14694102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of 2-bromo-5,6-dichloro-1-beta-D-ribofuranosyl benzimidazole riboside and inhibitors of DNA, RNA, and protein synthesis on human cytomegalovirus genome maturation.
    McVoy MA; Nixon DE
    J Virol; 2005 Sep; 79(17):11115-27. PubMed ID: 16103162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions among antiviral drugs acting late in the replication cycle of human cytomegalovirus.
    Evers DL; Komazin G; Shin D; Hwang DD; Townsend LB; Drach JC
    Antiviral Res; 2002 Oct; 56(1):61-72. PubMed ID: 12323400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms.
    Evers DL; Komazin G; Ptak RG; Shin D; Emmer BT; Townsend LB; Drach JC
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3918-27. PubMed ID: 15388453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human cytomegalovirus resistance to deoxyribosylindole nucleosides maps to a transversion mutation in the terminase subunit-encoding gene UL89.
    Gentry BG; Phan Q; Hall ED; Breitenbach JM; Borysko KZ; Kamil JP; Townsend LB; Drach JC
    Antimicrob Agents Chemother; 2015 Jan; 59(1):226-32. PubMed ID: 25348532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Guinea pig cytomegalovirus resistant to the DNA maturation inhibitor BDCRB.
    Ourahmane A; Sauer A; Nixon DE; Murphy C; Mondello M; Douglass Chiu E; Siegmund S; Wang JB; McVoy MA
    Antiviral Res; 2018 Jun; 154():44-50. PubMed ID: 29649495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole.
    Zacny VL; Gershburg E; Davis MG; Biron KK; Pagano JS
    J Virol; 1999 Sep; 73(9):7271-7. PubMed ID: 10438815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of action of the ribopyranoside benzimidazole GW275175X against human cytomegalovirus.
    Underwood MR; Ferris RG; Selleseth DW; Davis MG; Drach JC; Townsend LB; Biron KK; Boyd FL
    Antimicrob Agents Chemother; 2004 May; 48(5):1647-51. PubMed ID: 15105116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dramatic effects of 2-bromo-5,6-dichloro-1-beta-D-ribofuranosyl benzimidazole riboside on the genome structure, packaging, and egress of guinea pig cytomegalovirus.
    Nixon DE; McVoy MA
    J Virol; 2004 Feb; 78(4):1623-35. PubMed ID: 14747528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity.
    Champier G; Couvreux A; Hantz S; Rametti A; Mazeron MC; Bouaziz S; Denis F; Alain S
    Antivir Ther; 2008; 13(5):643-54. PubMed ID: 18771048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amino acid ester prodrugs of 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole enhance metabolic stability in vitro and in vivo.
    Lorenzi PL; Landowski CP; Song X; Borysko KZ; Breitenbach JM; Kim JS; Hilfinger JM; Townsend LB; Drach JC; Amidon GL
    J Pharmacol Exp Ther; 2005 Aug; 314(2):883-90. PubMed ID: 15901797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of acetylated, tetrahalogenated benzimidazole D-ribonucleosides with enhanced activity against human cytomegalovirus.
    Hwang JS; Kregler O; Schilf R; Bannert N; Drach JC; Townsend LB; Bogner E
    J Virol; 2007 Nov; 81(21):11604-11. PubMed ID: 17728228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance.
    Piret J; Boivin G
    Antiviral Res; 2019 Mar; 163():91-105. PubMed ID: 30690043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products.
    Buerger I; Reefschlaeger J; Bender W; Eckenberg P; Popp A; Weber O; Graeper S; Klenk HD; Ruebsamen-Waigmann H; Hallenberger S
    J Virol; 2001 Oct; 75(19):9077-86. PubMed ID: 11533171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibilities of human cytomegalovirus clinical isolates and other herpesviruses to new acetylated, tetrahalogenated benzimidazole D-ribonucleosides.
    Hwang JS; Schilf R; Drach JC; Townsend LB; Bogner E
    Antimicrob Agents Chemother; 2009 Dec; 53(12):5095-101. PubMed ID: 19786605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.